Bimekizumab Long-term Efficacy in Patients with Moderate to Severe Plaque Psoriasis After Switching From Adalimumab, Ustekinumab, or Secukinumab: Results from Up to 4 Years of Total Treatment from BE BRIGHT and BE RADIANT. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 6, p. s433, 2024. DOI: 10.25251/skin.8.supp.433. Disponível em: https://skin.dermsquared.com/skin/article/view/3092. Acesso em: 24 jun. 2025.